Boston-based pharmaceutical company Vertex has published promising interim analysis from two Phase III studies of a triple combination therapy of VX-445, tezacaftor and ivacaftor for cystic fibrosis.
6 March 2019 News
19 February 2019 News
The UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has revised its previous rejection of Takeda’s Alunbrig (brigatinib) for adults with anaplastic lymphoma kinase (ALK) positive...
4 February 2019 Analysis
Air pollution is a leading cause of death globally, as well as being responsible for new cases of chronic respiratory illnesses, such as asthma and COPD, and lung cancer, it...
4 February 2019 News
Patient-led campaign organisation Just Treatment has written to the UK Prime Minister Theresa May and Secretary of State for Health and Social Care Matt Hancock calling on the government to...
31 January 2019 Analysis
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
30 January 2019 Comment
Globally, there are 9,052 marketed products for ENT disorders. Most of these pharmaceuticals are small molecules and generics that target G protein-coupled receptors (GPCRs), nuclear receptors, and microbial membranes.
12 February 2018 Comment
GlaxoSmithKline (GSK) is expected to have two of the top-five best-selling drugs in the respiratory market in 2018, maintaining its strong portfolio of products in this market.
20 August 2017
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA)...